ArticleChinese journal of integrative medicine2026
Neuroprotective Mechanism of Polygonatum sibiricum Polysaccharides in Alzheimer's Disease: Highlighting Role of PI3K-AKT Signalling Pathway and Leptin Receptor.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the action mechanism of Polygonatum sibiricum polysaccharides (PSP) in Alzheimer's disease (AD).
methodsNetwork pharmacology and molecular docking was used to identify the major active ingredients and potential targets of PSP in treating AD. Male Kunming mice were randomly divided into 6 groups by a simple randomization method: control, model, low-, medium-, and high-dose PSP, and donepezil groups (n=6 per group). An AD mice model was established by intraperitoneally injecting 120 mg/kg D-galactose and oral administration of 40 mg/kg AlCl
resultsNetwork pharmacology identified that PI3K-AKT was the key signalling pathway affected by PSP in AD mice. In vivo experiments showed that PSP significantly improved anxiety levels and cognitive learning abilities in AD mice, upregulated the expression ratios of p-PI3K/PI3K and p-AKT/AKT in brain tissue, enhanced the activity of LepR and NeuN, and reduced Tau protein accumulation and the expression levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (P<0.05 or P<0.01). LepR-KD further demonstrated that its deficiency attenuated PSP's neuroprotective effects on cognitive function and cortical neuronal survival.
conclusionPSP modulates the PI3K-AKT signalling pathway in a LepR-dependent manner, thereby attenuating aberrant Tau protein deposition and inflammatory cytokine activity, which may cause delayed AD pathogenesis.
Indexed as
Identifiers
41489778What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.